Neoprobe Q2 sees revenues, losses up
Oncology and cardiovascular device manufacturer Neoprobe of Dublin, Ohio, reported an increase in sales as well as net losses for its fiscal 2007 second quarter (end-June 30). The firm currently markets the neo2000 line of gamma detection systems and is developing radiopharmaceutical agents.
For the period, the reported unaudited net sales of $1.5 million, compared with fiscal 2006 second quarter net sales of $1.4 million. Net losses for the current quarter rose to $1.1 million, compared with net losses of $861,000 for the same period in the prior year.
The company said that its operating expenses increased slightly for the first half of 2007 compared with last year due to increased clinical trial activity for its Phase 2 Lymphoseek trial.
For the period, the reported unaudited net sales of $1.5 million, compared with fiscal 2006 second quarter net sales of $1.4 million. Net losses for the current quarter rose to $1.1 million, compared with net losses of $861,000 for the same period in the prior year.
The company said that its operating expenses increased slightly for the first half of 2007 compared with last year due to increased clinical trial activity for its Phase 2 Lymphoseek trial.